Contraceptive Implants

 

 Buy Article Permissions and Reprints

ABSTRACT

Implantable contraception has been extensively used worldwide. Implants are one of the most effective and reversible methods of contraception available. These devices may be particularly appropriate for certain populations of women, including women who cannot use estrogen-containing contraception. Implants are safe for use by women with many chronic medical problems. The newest implant, Implanon (Organon International, Oss, The Netherlands), is the only device currently available in the United States and was approved in 2006. It is registered for 3 years of pregnancy prevention. Contraceptive implants have failure rates similar to tubal ligation, and yet they are readily reversible with a return to fertility within days of removal. Moreover, these contraceptive devices can be safely placed in the immediate postpartum period, ensuring good contraceptive coverage for women who may be at risk for an unintended pregnancy. Irregular bleeding is a common side effect for all progestin-only contraceptive implants. Preinsertion counseling should address possible side effects, and treatment may be offered to women who experience prolonged or frequent bleeding.

REFERENCES

• 1 Gu S, Sivin I, Du M et al.. Effectiveness of Norplant implants through seven years: a large-scale study in China.  Contraception. 1995;  52(2) 99-103
  CrossrefPubMedGoogle Scholar
• 2 Meirik O, Farley T M, Sivin I. Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization.  Obstet Gynecol. 2001;  97(4) 539-547
  CrossrefPubMedGoogle Scholar
• 3 Bongaarts J, Johansson E. Future trends in contraceptive prevalence and method mix in the developing world.  Stud Fam Plann. 2002;  33(1) 24-36
  CrossrefPubMedGoogle Scholar
• 4 Croxatt H B. Progestin implants for female contraception.  Contraception. 2002;  65(1) 15-19
  CrossrefPubMedGoogle Scholar
• 5 Zheng S R, Zheng H M, Qian S Z, Sang G W, Kaper R F. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China.  Eur J Contracept Reprod Health Care. 1999;  4(2) 85-93
  CrossrefPubMedGoogle Scholar
• 6 Darney P D. The androgenicity of progestins.  Am J Med. 1995;  98(1A, suppl 1A) 104S-110S
  CrossrefPubMedGoogle Scholar
• 7 Bennink H J. The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant.  Eur J Contracept Reprod Health Care. 2000;  5(suppl 2) 12-20
  PubMedGoogle Scholar
• 8 Ma G, Song C, Sun H, Yang J, Leng X. A biodegradable levonorgestrel-releasing implant made of PCL/F68 compound as tested in rats and dogs.  Contraception. 2006;  74(2) 141-147
  CrossrefPubMedGoogle Scholar
• 9 Oettinger M, Barak S, Oettinger-Barak O, Ophira E. Subcutaneous implantation of pure crystalline estradiol pellets for conception control.  Gynecol Obstet Invest. 2005;  59(3) 119-125
  CrossrefPubMedGoogle Scholar
• 10 Sivin I, Campodonico I, Kiriwat O et al.. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study.  Hum Reprod. 1998;  13(12) 3371-3378
  CrossrefPubMedGoogle Scholar
• 11 Croxatto H B. Mechanisms that explain the contraceptive action of progestin implants for women.  Contraception. 2002;  65(1) 21-27
  CrossrefPubMedGoogle Scholar
• 12 Diaz S, Pavez M, Miranda P, Robertson D N, Sivin I, Croxatto H B. A five-year clinical trial of levonorgestrel silastic implants (Norplant TM).  Contraception. 1982;  25(5) 447-456
  CrossrefPubMedGoogle Scholar
• 13 Sivin I, Lähteenmäki P, Ranta S et al.. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants.  Contraception. 1997;  55(2) 81-85
  CrossrefPubMedGoogle Scholar
• 14 Brache V, Faúndes A, Johansson E, Alvarez F. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants.  Contraception. 1985;  31(3) 261-273
  CrossrefPubMedGoogle Scholar
• 15 Dunson T R, Blumenthal P D, Alvarez F et al.. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus.  Fertil Steril. 1998;  69(2) 258-266
  CrossrefPubMedGoogle Scholar
• 16 Croxatto H D, Diaz S, Pavez M, Croxatto H B. Histopathology of the endometrium during continuous use of levonorgestrel. In: Zatuchni GI, Goldsmith A, Shelton JD, Sciarra KK Long-Acting Contraceptive Delivery Systems. Philadelphia, PA; Harper & Row 1983: 290-295
  Google Scholar
• 17 Shaaban M M, Segal S, Salem H T, Ghaneimah S A, Khalifa E A, Ahmed A G. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.  Fertil Steril. 1993;  59(5) 998-1002
  PubMedGoogle Scholar
• 18 Davies G C, Feng L X, Newton J R, Van Beek A, Coelingh-Bennink H J. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel.  Contraception. 1993;  47(3) 251-261
  CrossrefPubMedGoogle Scholar
• 19 Croxatto H B, Mäkäräinen L. The pharmacodynamics and efficacy of Implanon. An overview of the data.  Contraception. 1998;  58(6, suppl) 91S-97S
  CrossrefPubMedGoogle Scholar
• 20 Power J, French R, Cowan F. Subdermal implantable contraception versus other forms of reversible contraceptives or other implants as effective methods for preventing pregnancy.  Cochrane Database Syst Rev. 2007;  (3) CD001326
  PubMedGoogle Scholar
• 21 Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia.  Contraception. 2005;  71(4) 306-308
  CrossrefPubMedGoogle Scholar
• 22 Matiluko A A, Soundararjan L, Hogston P. Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz.  J Fam Plann Reprod Health Care. 2007;  33(4) 277-278
  CrossrefPubMedGoogle Scholar
• 23 World Health Organization .Medical Eligibility Criteria for Contraceptive Use 2008 Update. Geneva, Switzerland; World Health Organization 2008 WHO/RHR/09.19
  Google Scholar
• 24 Darney P, Patel A, Rosen K, Shapiro L S, Kaunitz A M. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials.  Fertil Steril. 2009;  91(5) 1646-1653
  CrossrefPubMedGoogle Scholar
• 25 Sivin I. Contraception with NORPLANT implants.  Hum Reprod. 1994;  9(10) 1818-1826
  PubMedGoogle Scholar
• 26 Huber J, Wenzl R. Pharmacokinetics of Implanon. An integrated analysis.  Contraception. 1998;  58(6, suppl) 85S-90S
  CrossrefPubMedGoogle Scholar
• 27 Croxatto H B, Urbancsek J, Massai R, Coelingh Bennink H, van Beek A. Implanon Study Group . A multicentre efficacy and safety study of the single contraceptive implant Implanon.  Hum Reprod. 1999;  14(4) 976-981
  CrossrefPubMedGoogle Scholar
• 28 Zheng S R, Zheng H M, Qian S Z, Sang G W, Kaper R F. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant.  Contraception. 1999;  60(1) 1-8
  CrossrefPubMedGoogle Scholar
• 29 Funk S, Miller M M, Mishell Jr D R Implanon US Study Group et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.  Contraception. 2005;  71(5) 319-326
  CrossrefPubMedGoogle Scholar
• 30 Cheng L, Zhu H, Wang A, Ren F, Chen J, Glasier A. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel.  Hum Reprod. 2000;  15(9) 1969-1972
  CrossrefPubMedGoogle Scholar
• 31 Archer D F, Philput C B, Levine A S et al.. Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users.  Contraception. 2008;  78(2) 106-112
  CrossrefPubMedGoogle Scholar
• 32 Weisberg E, Hickey M, Palmer D et al.. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users.  Hum Reprod. 2009;  24(8) 1852-1861
  CrossrefPubMedGoogle Scholar
• 33 Buasang K, Taneepanichskul S. Efficacy of celecoxib on controlling irregular uterine bleeding secondary to Jadelle use.  J Med Assoc Thai. 2009;  92(3) 301-307
  PubMedGoogle Scholar
• 34 Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A. Hormonal treatment for bleeding irregularities in Norplant implant users.  Am J Obstet Gynecol. 1996;  174(3) 919-922
  CrossrefPubMedGoogle Scholar
• 35 Subakir S B, Setiadi E, Affandi B, Pringgoutomo S, Freisleben H J. Benefits of vitamin E supplementation to Norplant users—in vitro and in vivo studies.  Toxicology. 2000;  148(2–3) 173-178
  CrossrefPubMedGoogle Scholar
• 36 Croxatto H B. Progestin implants.  Steroids. 2000;  65(10–11) 681-685
  CrossrefPubMedGoogle Scholar
• 37 Biswas A, Biswas S, Viegas O A. Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests—a randomized comparative study with Norplant implants.  Contraception. 2004;  70(5) 379-382
  CrossrefPubMedGoogle Scholar
• 38 Nasr A, Nafeh H M. Effect of etonogestrel contraceptive implant (Implanon) on portal blood flow and liver functions.  Contraception. 2009;  79(3) 236-239
  CrossrefPubMedGoogle Scholar
• 39 World Health Organization .Medical Eligibility Criteria for Contraceptive Use. 3rd ed. Geneva, Switzerland; World Health Organization 2004
  Google Scholar
• 40 Biswas A, Viegas O A, Coeling Bennink H J, Korver T, Ratnam S S. Implanon contraceptive implants: effects on carbohydrate metabolism.  Contraception. 2001;  63(3) 137-141
  CrossrefPubMedGoogle Scholar
• 41 Vicente L, Mendonça D, Dingle M, Duarte R, Boavida J M. Etonogestrel implant in women with diabetes mellitus.  Eur J Contracept Reprod Health Care. 2008;  13(4) 387-395
  CrossrefPubMedGoogle Scholar
• 42 Beerthuizen R, van Beek A, Massai R, Mäkäräinen L, Hout J, Bennink H C. Bone mineral density during long-term use of the progestogen contraceptive implant Implanon compared to a non-hormonal method of contraception.  Hum Reprod. 2000;  15(1) 118-122
  CrossrefPubMedGoogle Scholar
• 43 Reinprayoon D, Taneepanichskul S, Bunyavejchevin S et al.. Effects of the etonogestrel-releasing contraceptive implant (Implanon on parameters of breastfeeding compared to those of an intrauterine device.  Contraception. 2000;  62(5) 239-246
  CrossrefPubMedGoogle Scholar
• 44 Halderman L D, Nelson A L. Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns.  Am J Obstet Gynecol. 2002;  186(6) 1250-1256 discussion 1256-1258
  CrossrefPubMedGoogle Scholar
• 45 Walch K, Unfried G, Huber J et al.. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis—a pilot study.  Contraception. 2009;  79(1) 29-34
  CrossrefPubMedGoogle Scholar
• 46 Shokeir T, Amr M, Abdelshaheed M. The efficacy of Implanon for the treatment of chronic pelvic pain associated with pelvic congestion: 1-year randomized controlled pilot study.  Arch Gynecol Obstet. 2009;  280(3) 437-443
  CrossrefPubMedGoogle Scholar
• 47 Shulman L P, Gabriel H. Management and localization strategies for the nonpalpable Implanon rod.  Contraception. 2006;  73(4) 325-330
  CrossrefPubMedGoogle Scholar
• 48 Mourtialon P, Tixier H, Loffroy R et al.. Vascular complication after insertion of a subcutaneous contraceptive implant.  Acta Obstet Gynecol Scand. 2008;  87(11) 1256-1258
  CrossrefPubMedGoogle Scholar
• 49 Levine J P, Sinofsky F E, Christ M F. Implanon US Study Group . Assessment of Implanon insertion and removal.  Contraception. 2008;  78(5) 409-417
  CrossrefPubMedGoogle Scholar
• 50 Evans R, Holman R, Lindsay E. Migration of Implanon: two case reports.  J Fam Plann Reprod Health Care. 2005;  31(1) 71-72
  CrossrefPubMedGoogle Scholar
• 51 National Institutes of Health .Clinical trials database. Available at: http://clinicaltrials.gov/ct2/show/NCT00847587?term=implanon&rank=5 Accessed August 29, 2009
  Google Scholar
• 52 Organon International .Implanon package insert. Oss, The Netherlands; Organon July 2006
  Google Scholar

Raegan McDonald-MosleyM.D. M.P.H. 

Clinical Instructor, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine

4940 Eastern Avenue, A Building, Baltimore, Maryland 21224

Email: rmcdon19@jhmi.edu